ECG
ABBV icon

Edge Capital Group’s AbbVie ABBV Stock Holding History

Edge Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$951K Buy
5,349
+1,151
+27% +$212K 0.04% 169
2024
Q3 		$829K Buy
4,198
+250
+6% +$46.7K 0.04% 182
2024
Q2 		$677K Sell
3,948
-276
-7% -$45.7K 0.03% 192
2024
Q1 		$769K Sell
4,224
-92
-2% -$15.9K 0.04% 187
2023
Q4 		$669K Sell
4,316
-388
-8% -$56.6K 0.04% 189
2023
Q3 		$701K Sell
4,704
-405
-8% -$59.5K 0.05% 173
2023
Q2 		$688K Sell
5,109
-386
-7% -$56.6K 0.04% 195
2023
Q1 		$876K Buy
5,495
+17
+0.3% +$2.6K 0.05% 174
2022
Q4 		$885K Buy
5,478
+62
+1% +$9.51K 0.06% 150
2022
Q3 		$727K Sell
5,416
-3
-0.1% -$430 0.06% 155
2022
Q2 		$830K Buy
5,419
+440
+9% +$67.2K 0.07% 153
2022
Q1 		$807K Sell
4,979
-508
-9% -$73.8K 0.06% 162
2021
Q4 		$743K Buy
5,487
+311
+6% +$36.7K 0.05% 165
2021
Q3 		$558K Sell
5,176
-26
-0.5% -$2.97K 0.04% 172
2021
Q2 		$586K Sell
5,202
-198
-4% -$22.3K 0.05% 173
2021
Q1 		$584K Sell
5,400
-9,427
-64% -$1.01M 0.05% 171
2020
Q4 		$1.6M Buy
14,827
+9,529
+180% +$916K 0.13% 109
2020
Q3 		$464K Buy
5,298
+744
+16% +$70K 0.05% 166
2020
Q2 		$447K Sell
4,554
-356
-7% -$31.3K 0.05% 158
2020
Q1 		$374K Sell
4,910
-369
-7% -$31.4K 0.04% 160
2019
Q4 		$467K Buy
5,279
+455
+9% +$37.8K 0.05% 171
2019
Q3 		$365K Sell
4,824
-1,540
-24% -$106K 0.04% 187
2019
Q2 		$463K Buy
6,364
+320
+5% +$25.2K 0.04% 178
2019
Q1 		$487K Sell
6,044
-2,675
-31% -$219K 0.05% 173
2018
Q4 		$804K Buy
+8,719
New +$767K 0.09% 122

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Edge Capital Group's ABBV Position: Q4 2024 in Review

Edge Capital Group increased its AbbVie (ABBV) stake by 27% in Q4 2024, buying an estimated $212K and bringing the position to 5,349 shares worth $951K. The position accounts for 0.04% of the portfolio, ranked #169.

Edge Capital Group first reported a position in ABBV in Q4 2018 and has held it in 25 quarters since. The position peaked at $1.6M in Q4 2020. 3,744 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.

  • Edge Capital Group held 5,349 shares of AbbVie worth $951K as of Q4 2024.
  • Edge Capital Group bought 1,151 AbbVie shares in Q4 2024, an estimated $212K.
  • AbbVie made up 0.04% of Edge Capital Group's portfolio in Q4 2024, its #169 holding.
  • Edge Capital Group first reported a position in AbbVie in Q4 2018 and has held it in 25 quarters since.
  • Edge Capital Group's AbbVie position peaked at $1.6M in Q4 2020.
  • 3,744 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.

Based on Edge Capital Group's 13F filing for Q4 2024, filed 4 Feb 2025.